Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

NCT05719714 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Chronic Kidney Diseases
Heart Failure With Preserved Ejection Fraction
Kidney Diseases
Heart Failure

Interventions

DRUG: Dapagliflozin 10 MG [Farxiga]

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]